Abstract
Over the past decades, nanomedicine, the medical application of nanotechnology, has been extensively investigated as a promising approach in treating different inflammatory disorders and conditions. Nanomedicine provides a wide range of engineered nanomaterials, such as polymeric nanoparticles (NPs), lipid-based NPs, liposomes, silica NPs, metallic NPs, etc. Nanomaterial-based drug delivery systems exhibit multiple advantages such as the ability to pass through different physiological barriers within the body and specifically deliver drugs to the required sites without affecting healthy cells and tissues. Enormous amounts of in-vitro and in-vivo researches were previously conducted by many research groups to validate the positive contribution that nanomedicine has regarding the treatment of inflammation and its associated illnesses. The scope of this review paper is to overview the current status of using nanomaterials in the treatment of inflammatory diseases, with an emphasis on asthma, rheumatoid arthritis, inflammatory bowel disease, gout and atherosclerosis. The future prospects of using nanomaterials for inflammatory diseases were also briefly discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Availability of data and material
Not applicable.
Code availability
Not applicable.
References
Alaarg A, Jordan NY, Verhoef JJ et al (2016) Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment. Int J Nanomed 11:5027–5040. https://doi.org/10.2147/IJN.S115995
Aletaha D, Kapral T, Smolen JS (2003) Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 62(5):482–486. https://doi.org/10.1136/ard.62.5.482
Arif M, Chi Z, Liu YJ, Liu CG (2020) Preparation, characterization, and in vitro drug release behavior of thiolated alginate nanoparticles loaded budesonide as a potential drug delivery system toward inflammatory bowel diseases. J Biomater Sci Polym 31:e2299
Banik B, Fattahi P, Brown J (2016) Polymeric nanoparticles: the future of nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 8(2):271–299. https://doi.org/10.1002/wnan
Belali N, Wathoni N, Muchtaridi M (2019) Advances in orally targeted drug delivery to colon. J Adv Pharm Technol Res 10(3):100–106. https://doi.org/10.4103/japtr.JAPTR_26_19
Belyakov I, Zimmermann E, Isakov D et al (2012) Effect of targeted drug delivery with G5-MTX dendrimers on induced T regulatory (iTreg) CD4+ T cells in an inflammatory bowel disease (IBD) colitis model. J Immunol 188(1 Supplement):52.1
Bergheanu S, Bodde M, Jukema J (2017) Pathophysiology and treatment of atherosclerosis. Neth Heart J 25(4):231–242
Bhalekar MR, Madgulkar AR, Desale PS et al (2017) Formulation of piperine solid lipid nanoparticles (SLN) for treatment of rheumatoid arthritis. Drug Dev Ind Pharm 43(6):1003–1010. https://doi.org/10.1080/03639045.2017.1291666
Bhaskar K, Anbu J, Ravichandiran V et al (2009) Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis 26(8):6. https://doi.org/10.1186/1476-511X-8-6
Bi F, Zhang J, Su Y et al (2009) Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis. Biomaterials 30:5125–5130. https://doi.org/10.1016/j.biomaterials.2009.06.006
Boas U, Heegaard P (2004) Dendrimers in drug research. Chem Soc Rev 33(1):43–63. https://doi.org/10.1039/b309043b
Bozzuto G, Molinari A (2015) Liposomes as nanomedical devices. Int J Nanomed 10:975–999. https://doi.org/10.2147/IJN.S68861
Brusini R, Varna M, Couvreur P (2020) Advanced nanomedicines for the treatment of inflammatory diseases. Adv Drug Deliv Rev 157:161–178. https://doi.org/10.1016/j.addr.2020.07.010
Carneiro MF, Machado AR, Antunes LM et al (2020) Gold-coated superparamagnetic iron oxide nanoparticles attenuate collagen-induced arthritis after magnetic targeting. Biol Trace Elem Res 194(2):502–513. https://doi.org/10.1007/s12011-019-01799-z
Chen X, Huang W, Wong BC et al (2012) Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomed 7:1139–1148. https://doi.org/10.2147/IJN.S28011
D’Haens G (2007) Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56:725–732. https://doi.org/10.1136/gut.2006.103564
Del Grossi Moura M, Cruz Lopes L, Silva MT et al (2018) Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: systematic review protocol. Medicine 97(41):e12658. https://doi.org/10.1097/MD.0000000000012658
Dianzani C, Foglietta F, Ferrara B et al (2017) Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: effects in an in vivo model. World J Gastroenterol 23(23):4200–4210. https://doi.org/10.3748/wjg.v23.i23.4200
Diaz-Borjon A, Weyand C, Goronzy J (2006) Treatment of chronic inflammatory diseases with biologic agents: opportunities and risks for the elderly. Exp Gerontol 41(12):1250–1255. https://doi.org/10.1016/j.exger.2006.10.010
Ely LS, Engroff P, Guiselli SR, Cardoso GC et al (2015) Use of anti-inflammatory and analgesic drugs in an elderly population registered with a Family Health Program. Rev Bras Geriatr Gerontol 18(3):475–485. https://doi.org/10.1590/1809-9823.2015.14141
Furman D, Campisi J, Verdin E, Carrera-Bastos P et al (2019) Chronic inflammation in the etiology of disease across the life span. Nat Med 25(12):1822–1832. https://doi.org/10.1038/s41591-019-0675-0
Gao W, Sun Y, Cai M, Zhao Y et al (2018) Copper sulfide nanoparticles as a photothermal switch for TRPV1 signaling to attenuate atherosclerosis. Nat Commun 9(1):231. https://doi.org/10.1038/s41467-017-02657-z
Goldstein IM, Snyderman R, Gallin JI (1992) Inflammation: basic principles and clinical correlates. Raven Press
Guo Q, Wang Y, Xu D, Nossent J et al (2018) Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 6:15. https://doi.org/10.1038/s41413-018-0016-9
Hodges P, Kelly P (2020) Inflammatory bowel disease in Africa: what is the current state of knowledge? Int Health 12(3):222–230. https://doi.org/10.1093/inthealth/ihaa005
Hua S, Marks E, Schneider JJ et al (2015) Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine 11(5):1117–1132. https://doi.org/10.1016/j.nano.2015.02.018
Huang YJ, Shiau AL, Chen SY et al (2012) Multivalent structure of galectin-1-nanogold complex serves as potential therapeutics for rheumatoid arthritis by enhancing receptor clustering. Eur Cell Mater 23:170–181. https://doi.org/10.22203/ecm.v023a13
Jackson JK, Zhang X, Llewellen S et al (2004) The characterization of novel polymeric paste formulations for intratumoral delivery. Int J Pharm 270(1–2):185–198. https://doi.org/10.1016/j.ijpharm.2003.10.01
Janakiraman K, Krishnaswami V, Rajendran V et al (2018) Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights. Mater Today Commun 17:200–213. https://doi.org/10.1016/j.mtcomm.2018.09.011
Jeevanandam J, Barhoum A, Chan YS et al (2018) Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol 9:1050–1074. https://doi.org/10.3762/bjnano.9.98
Jung G-U, Han J-Y, Hwang K-G et al (2018) Effects of conventional synthetic disease-modifying antirheumatic drugs on response to periodontal treatment in patients with rheumatoid arthritis. Biomed Res Int. https://doi.org/10.1155/2018/1465402
Kabanov AV, Vinogradov SV (2009) Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed Engl 48(30):5418–5429. https://doi.org/10.1002/anie.200900441
Kamaly N, Fredman G, Fojas JJ et al (2016) Targeted Interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis. ACS Nano 10:5280–5292. https://doi.org/10.1021/acsnano.6b01114
Kan S, Hariyadi DM, Grainge et al (2020) Airway epithelial-targeted nanoparticles for asthma therapy. Am J Physiol Lung Cell Mol Physiol 318(3):500–509. https://doi.org/10.1152/ajplung.00237.2019
Katsuki S, Matoba T, Nakashiro S et al (2014) Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 129(8):896–906. https://doi.org/10.1161/CIRCULATIONAHA.113.002870
Kenyon NJ, Bratt JM, Lee J et al (2013) Self-assembling nanoparticles containing dexamethasone as a novel therapy in allergic airways inflammation. PLoS ONE 8(10):e77730. https://doi.org/10.1371/journal.pone.0077730
Kim BY, Rutka JT, Chan WCJ (2010) Nanomedicine. N Engl J Med 363(25):2434–2443. https://doi.org/10.1056/NEJMra0912273
Kim Y, Oh H-C, Park JW et al (2017) Diagnosis and treatment of inflammatory joint disease. Hip Pelvis 29(4):211–222. https://doi.org/10.5371/hp.2017
Kirdaite G, Leonaviciene L, Bradunaite R et al (2019) Antioxidant effects of gold nanoparticles on early stage of collagen-induced arthritis in rats. Res Vet Sci 124:32–37. https://doi.org/10.1016/j.rvsc.2019.02.002
Kishore N, Raja MD, Kumar CS et al (2016) Lipid carriers for delivery of celecoxib: in vitro, in vivo assessment of nanomedicine in rheumatoid arthritis. Eur J Lipid Sci Technol 118:949–958
Kiyani MM, Butt MA, Rehman H et al (2019) Antioxidant and anti-gout effects of orally administered zinc oxide nanoparticles in gouty mice. J Trace Elem Med Biol 56:169–177. https://doi.org/10.1016/j.jtemb.2019.08.012
Köhler BM, Günther J, Kaudewitz D et al (2019) Current therapeutic options in the treatment of rheumatoid arthritis. J Clin Med 8(7):938. https://doi.org/10.3390/jcm8070938
Konduri KS, Nandedkar S, Düzgünes N et al (2003) Efficacy of liposomal budesonide in experimental asthma. J Allergy Clin Immunol 11(2):321–327. https://doi.org/10.1067/mai.2003.104
Kumar J, Newton AMJ (2017) Rifaximin–chitosan nanoparticles for inflammatory bowel disease (IBD). Recent Pat Inflamm Allergy Drug Discov 11(1):41–52. https://doi.org/10.2174/1872213X10666161230111226
Kumar M, Kong X, Behera AK et al (2003) Chitosan IFN-γ-pDNA nanoparticle (CIN) therapy for allergic asthma. Genet Vaccines Ther 1(1):1–10. https://doi.org/10.1186/1479-0556-1-3
Kumar V, Leekha A, Tyagi A et al (2017) Preparation and evaluation of biopolymeric nanoparticles as drug delivery system in effective treatment of rheumatoid arthritis. Pharm Res 34:654–677
Lagnoux D, Darbre T, Schmitz ML et al (2005) Inhibition of mitosis by glycopeptide dendrimer conjugates of colchicine. Chemistry 11(13):3941–3950. https://doi.org/10.1002/chem.200401294
Lee S-M, Kim HJ, Ha Y-J et al (2013) Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional nanoparticles. ACS Nano 7(1):50–57. https://doi.org/10.1021/nn301215q
Lee GY, Kim J-H, Choi KY et al (2015) Hyaluronic acid nanoparticles for active targeting atherosclerosis. Biomaterials 53:341–348. https://doi.org/10.1016/j.biomaterials.2015.02.089
Lee SH, Bajracharya R, Min JY et al (2020) Strategic approaches for colon targeted drug delivery: an overview of recent advancements. Pharmaceutics 12(1):68–75. https://doi.org/10.3390/pharmaceutics12010068
Leuschner F, Dutta P, Gorbatov R et al (2011) Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29:1005–1010. https://doi.org/10.1038/nbt.1989
Li J, Chen L, Xu X, Fan Y et al (2020) Targeted combination of antioxidative and anti-inflammatory therapy of rheumatoid arthritis using multifunctional dendrimer-entrapped gold nanoparticles as a platform. Small 16(49):e2005661. https://doi.org/10.1002/smll.202005661
Lobatto ME, Fayad ZA, Silvera S et al (2010) Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm 7:2020–2029
Matsuo Y, Ishihara T, Ishizaki J et al (2009) Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol 260(1):33–38. https://doi.org/10.1016/j.cellimm.2009.07.004
McHugh JM, McHugh WB (2000) Pain: neuroanatomy, chemical mediators, and clinical implications. AACN Clin Issues 11(2):168–178. https://doi.org/10.1097/00044067-200005000-00003
Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454(7203):428–435. https://doi.org/10.1038/nature07201454:428
Mody VV, Siwale R, Singh A et al (2010) Introduction to metallic nanoparticles. J Pharm Bioallied Sci 2(4):282–289. https://doi.org/10.4103/0975-7406.72127
Moulari B, Pertuit D, Pellequer Y et al (2008) The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials 29(34):4554–4560. https://doi.org/10.1016/j.biomaterials
Moulari B, Béduneau A, Pellequer Y et al (2014) Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. J Control Release 188:9–17. https://doi.org/10.1016/j.jconrel.2014.05.046
Murdoch JR, Lloyd CM (2010) Chronic inflammation and asthma. Mutat Res 690(1–2):24–39. https://doi.org/10.1016/j.mrfmmm
Muthukoori S, Narayanan N, Chandra MS et al (2013) Enzyme-entrapped mesoporous silica for treatment of uric acid disorders. J Biomed Nanotechnol 9:907–1114. https://doi.org/10.1166/jbn.2013.1588
Naeem M, Bae J, Oshi MA et al (2018a) Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. Int J Nanomed 13:1225–1240. https://doi.org/10.2147/IJN.S157566
Naeem M, Oshi MA, Kim J, Lee J, Biology M et al (2018b) pH-triggered surface charge-reversal nanoparticles alleviate experimental murine colitis via selective accumulation in inflamed colon regions. Nanomedicine 14(3):823–834. https://doi.org/10.1016/j.nano.2018.01.003
Naeem M, Lee J, Oshi MA, Cao J et al (2020) Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis. Acta Biomater 116:368–382. https://doi.org/10.1016/j.actbio.2020.09.017
Nasr M, Najlah M, D’Emanuele A et al (2014) PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization. Int J Pharm 461(1–2):242–250. https://doi.org/10.1016/j.ijpharm.2013
Oliveira IM, Gonçalves C, Shin ME et al (2020) Enzymatically crosslinked tyramine-gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment. Drug Deliv Transl Res. https://doi.org/10.1007/s13346-020-00855-9
Oshi MA, Naeem M, Bae J, Kim J et al (2018) Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease. Carbohydr Polym 198:434–442. https://doi.org/10.1016/j.carbpol.2018.06.107
Oshi MA, Lee J, Naeem M, Hasan N et al (2020) Curcumin nanocrystal/pH-responsive polyelectrolyte multilayer core–shell nanoparticles for inflammation-targeted alleviation of ulcerative colitis. Biomacromol 21:3571–3581. https://doi.org/10.1021/acs.biomac.0c00589
Pahwa R, Goyal A, Bansal P et al (2020) Chronic inflammation. StatPearls [Internet]. StatPearls Publishing, Treasure Island
Paoletti R, Gotto AM, Hajjar DP (2004) Inflammation in atherosclerosis and implications for therapy. Circulation 109:III20–III26. https://doi.org/10.1161/01.CIR.0000131514.71167.2e
Parashar P, Mazhar I, Kanoujia J et al (2019a) Appraisal of anti-gout potential of colchicine-loaded chitosan nanoparticle gel in uric acid-induced gout animal model. Arch Physiol Biochem 18:1–11. https://doi.org/10.1080/13813455.2019.1702702
Park HS, Kim KH, Jang S et al (2010) Attenuation of allergic airway inflammation and hyperresponsiveness in a murine model of asthma by silver nanoparticles. Int J Nanomed 5:505–515. https://doi.org/10.2147/ijn.s11664
Park HJ, Sohn J-H, Kim Y-J et al (2015) Acute exposure to silica nanoparticles aggravate airway inflammation: different effects according to surface characteristics. Exp Mol Med 47(7):e173. https://doi.org/10.1038/emm.2015.50
Patel M, Shaw DJ (2015) A review of standard pharmacological therapy for adult asthma—steps 1 to 5. Chron Respir Dis 12(2):165–176. https://doi.org/10.1177/1479972315573529
Patra JK, Das G, Fraceto LF et al (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16(1):71. https://doi.org/10.1186/s12951-018-0392-8
Peng L-H, Wei W, Shan Y-H et al (2017) Sustained release of piroxicam from solid lipid nanoparticle as an effective anti-inflammatory therapeutics in vivo. Drug Dev Ind Pharm 43(1):55–66. https://doi.org/10.1080/03639045.2016
Pillinger MH, Mandell BF (2020) Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum 50:S24–S30. https://doi.org/10.1016/j.semarthrit.2020.04.010
Prilepskii AY, Serov NS, Kladko DV et al (2020) Nanoparticle-based approaches towards the treatment of atherosclerosis. Pharmaceutics 12(11):1056
Ragab G, Elshahaly M, Bardin T (2017) Gout: an old disease in new perspective—a review. J Adv Res 8(5):495–511
Raj R, Mongia P, Ram A, Jain NK (2016) Enhanced skin delivery of aceclofenac via hydrogel-based solid lipid nanoparticles. Artif Cells Nanomed Biotechnol 44:1434
Ross RJ (1986) The pathogenesis of atherosclerosis—an update. N Engl J Med 314(8):488–500. https://doi.org/10.1056/NEJM198602203140806
Ruiz-Miyazawa KW, Staurengo-Ferrari L, Pinho-Ribeiro FA et al (2018) 15d-PGJ2-loaded nanocapsules ameliorate experimental gout arthritis by reducing pain and inflammation in a PPAR-gamma-sensitive manner in mice. Sci Rep 8(1):13979. https://doi.org/10.1038/s41598-018-32334-0
Santonopoulos A, Margaritis M, Lee R, Channon K et al (2012) Statins as antiinflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 18(11):1519–15130. https://doi.org/10.2174/138161212799504803
Singh HP, Utreja P, Tiwary AK, Jain S (2009) Elastic liposomal formulation for sustained delivery of colchicine: in vitro characterization and in vivo evaluation of anti-gout activity. AAPS J 11(1):54–64. https://doi.org/10.1208/s12248-008-9078-8
Straube S, Tramèr MR, Moore RA et al (2009) Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol 5(9):41. https://doi.org/10.1186/1471-230X-9-41
Suganya T (2012) Formulation and evaluation of polymeric nanoparticles as carriers of rosuvastatin calcium for oral administration. College of Pharmacy, Madurai Medical College, Madurai
Tang J, Lobatto ME, Hassing L et al (2015) Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci Adv 1(3):e1400223. https://doi.org/10.1126/sciadv.1400223
Tang H, Xiang D, Wang F et al (2017) 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice. Mol Med Rep 15:e1117
Thao LQ, Byeon HJ, Lee C et al (2016) Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues. Int J Pharm 497:268–276. https://doi.org/10.1016/j.ijpharm.2015.12.004
Tiwari S, Dwivedi H, Kymonil KM, Saraf SA (2015) Urate crystal degradation for treatment of gout: a nanoparticulate combination therapy approach. Drug Deliv Transl Res 5(3):219–230. https://doi.org/10.1007/s13346-015-0219-1
Trewyn BG, Nieweg JA, Zhao Y, Lin VSY (2008) Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane penetration. Chem Eng J 137:23–29
Vigne J, Cabella C, Dézsi L et al (2020) Nanostructured lipid carriers accumulate in atherosclerotic plaques of ApoE−/− mice. Nanomedicine 25:e102157. https://doi.org/10.1016/j.nano.2020.102157
Wang W, Zhu R, Xie Q, Li A et al (2012) Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomed 7:3667–3677. https://doi.org/10.2147/IJN.S30428
Wang Q, Yang Q, Cao X et al (2018a) Enhanced oral bioavailability and anti-gout activity of [6]-shogaol-loaded solid lipid nanoparticles. Int J Pharm 25(1–2):24–34. https://doi.org/10.1016/j.ijpharm.2018.08.028
Wang Y, Li L, Zhao W, Dou Y et al (2018b) Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity. ACS Nano 12:8943
Wang L, Feng M, Li Q, Qiu C, Chen R (2019) Advances in nanotechnology and asthma. Ann Transl Med 7(8):e180. https://doi.org/10.21037/atm.2019.04.62
Wassung K (1999) Asthma from the perspective of the patient. J Asthma 104:209–220. https://doi.org/10.3109/02770903.2013.860162
White J, Robert I (1999) Bronchial artery embolotherapy for control of acute hemoptysis. Chest 115(4):912–915. https://doi.org/10.1378/chest.115.4.912
Yang L, Chu J, Fix J (2002) Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm 20(235):1–15. https://doi.org/10.1016/s0378-5173(02)00004-2
Ye J, Wang Q, Zhou X, Zhang NJ (2008) Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm 352(1–2):273–279. https://doi.org/10.1016/j.ijpharm.2007.10.014
Zdanowicz MM (2007) Pharmacotherapy of asthma. Am J Pharm Educ 71(5):e98. https://doi.org/10.5688/aj710598
Zhai J, Mantaj J, Vllasaliu D (2018) Ascorbyl palmitate hydrogel for local, intestinal delivery of macromolecules. Pharmaceutics 10(4):e188. https://doi.org/10.3390/pharmaceutics10040188
Zhang J, Zu Y, Dhanasekara CS et al (2017) Detection and treatment of atherosclerosis using nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. https://doi.org/10.1002/wnan.1412
Zimmermann TS, Lee AC, Akinc A, Bramlage B et al (2006) RNAi-mediated gene silencing in non-human primates. Nature 441(7089):111–114. https://doi.org/10.1038/nature04688
Funding
No funding source.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing financial interest.
Ethics approval
Not applicable.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Oshi, M.A., Haider, A., Siddique, M.I. et al. Nanomaterials for chronic inflammatory diseases: the current status and future prospects. Appl Nanosci 12, 3097–3110 (2022). https://doi.org/10.1007/s13204-021-02019-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13204-021-02019-8